The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter
Open accessAbstract
In an effort to maximize outcomes, recent expert guidelines recommend more-intensive vancomycin dosing schedules to maintain vancomycin troughs between 15 and 20 mg/liter. The widespread use of these more-intensive regimens has been associated with an increase in vancomycin-induced nephrotoxicity reports. The purpose of this systematic literature review is to determine the nephrotoxicity potential of maintaining higher troughs in clinical practice. All studies pertaining to vancomycin-induced nephrotoxicity between 1996 and April 2012 were identified from PubMed, Embase, Cochrane Controlled Trial Registry, and Medline databases and analyzed according to Cochrane guidelines. Of the initial 240 studies identified, 38 were reviewed, and 15 studies met the inclusion criteria. Overall, higher troughs (≥15 mg/liter) were associated with increased odds of nephrotoxicity (odds ratio [OR], 2.67; 95% confidence interval [CI], 1.95 to 3.65) relative to lower troughs of <15 mg/liter. The relationship between a trough of ≥15 mg/liter and nephrotoxicity persisted when the analysis was restricted to studies that examined only initial trough concentrations (OR, 3.12; 95% CI, 1.81 to 5.37). The relationship between troughs of ≥15 mg/liter and nephrotoxicity persisted after adjustment for covariates known to independently increase the risk of a nephrotoxicity event. An incremental increase in nephrotoxicity was also observed with longer durations of vancomycin administration. Vancomycin-induced nephrotoxicity was reversible in the majority of cases, with short-term dialysis required only in 3% of nephrotoxic episodes. The collective literature indicates that an exposure-nephrotoxicity relationship for vancomycin exists. The probability of a nephrotoxic event increased as a function of the trough concentration and duration of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & workgroup, T. A. (2004) · Critical Care · doi:10.1186/cc2872 · Cited by 6,781
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Naimi, T. S. (2003) · JAMA · doi:10.1001/jama.290.22.2976 · Cited by 1,688
Methicillin-Resistant Staphylococcus aureus Disease in Three Communities
Fridkin, S. K., Hageman, J. C., Morrison, M., Sanza, L. T., Como-Sabetti, K., Jernigan, J. A., Harriman, K., Harrison, L. H., Lynfield, R., & Farley, M. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043252 · Cited by 1,493
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Self-citationWunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Self-citationvan Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
Self-citationKullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463 · cited 9×
“Despite its adoption, there are (10) limited data to suggest that maintenance of vancomycin trough values between 15 and 20 mg/liter improves outcomes (8, 10).”
BackgroundInfluentialPopovich, K. J., Weinstein, R. A., & Hota, B. (2008) · Clinical Infectious Diseases · doi:10.1086/528716 · Cited by 378
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Vancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275
Bosso, J. A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P. B., Swindler, J., & Mauldin, P. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-11 · Cited by 252
Vancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Self-citationTelavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
Rubinstein, E., Lalani, T., Corey, G. R., Kanafani, Z. A., Nannini, E. C., Rocha, M. G., Rahav, G., Niederman, M. S., Kollef, M. H., Shorr, A. F., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq031 · Cited by 246
Clinical review: RIFLE and AKIN – time for reappraisal
Cruz, D. N., Ricci, Z., & Ronco, C. (2009) · Critical Care · doi:10.1186/cc7759 · Cited by 242
Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01708-10 · Cited by 226
Moore, C. L., Osaki-Kiyan, P., Haque, N. Z., Perri, M. B., Donabedian, S., & Zervos, M. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir764 · Cited by 220
Incidence and Risk Factors Influencing the Development of Vancomycin Nephrotoxicity in Children
McKamy, S., Hernandez, E., Jahng, M., Moriwaki, T., Deveikis, A., & Le, J. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.08.019 · Cited by 186
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
Wong-Beringer, A., Joo, J., Tse, E., & Beringer, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.013 · Cited by 178
Ingram, P. R., Lye, D. C., Tambyah, P. A., Goh, W. P., Tam, V. H., & Fisher, D. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn080 · Cited by 163
Cano, E. L., Haque, N. Z., Welch, V. L., Cely, C. M., Peyrani, P., Scerpella, E. G., Ford, K. D., Zervos, M. J., Ramirez, J. A., & Kett, D. H. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.12.013 · Cited by 161
Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity
Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.025 · Cited by 161
Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?
Hazlewood, K. A., Brouse, S. D., Pitcher, W. D., & Hall, R. G. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.031 · Cited by 139
Vancomycin nephrotoxicity: myths and facts.
Gupta, A., Biyani, M., & Khaira, A. (2011) · PubMed · Cited by 123
Zimmermann, A. E., Katona, B. G., & Plaisance, K. I. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04335.x · Cited by 123
Lahoti, A., Kantarjian, H. M., Salahudeen, A. K., Ravandi, F., Cortes, J. E., Faderl, S. H., O'Brien, S. M., Wierda, W. G., & Mattiuzzi, G. N. (2010) · Cancer · doi:10.1002/cncr.25306 · Cited by 116
Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V. I., Fangtang, J. T., Martin, C. G., RAAD, I. I., Whimbey, E. E., Manzullo, E. F., & Bodey, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l · Cited by 109
Kullar, R., Leonard, S. N., Davis, S. L., Delgado, G., Pogue, J. M., Wahby, K. A., Falcione, B. A., & Rybak, M. J. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.441 · Cited by 109
Hermsen, E. D., Hanson, M., Sankaranarayanan, J., Stoner, J. A., Florescu, M. C., & Rupp, M. E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903413514 · Cited by 102
King, D. W., & Smith, M. A. (2004) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.03.013 · Cited by 97
Minejima, E., Choi, J. J., Beringer, P. M., Lou, M., Tse, E., & Wong‐Beringer, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00173-11 · Cited by 94
Protective Effects of Different Antioxidants and Amrinone on Vancomycin‐Induced Nephrotoxicity
Çelik, İ., Cihangiroğlu, M., İlhan, N., Akpolat, N., & Akbulut, H. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_153.x · Cited by 92
Kullar, R., Davis, S. L., Taylor, T. N., Kaye, K. S., & Rybak, M. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01017.x · Cited by 86
Çetin, H., Olgar, Ş., Öktem, F., et al. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04695.x · Cited by 81
Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery
Hutschala, D., Kinstner, C. M., Skhirdladze, K., et al. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181a97272 · Cited by 78
Walraven, C. J., North, M., Marr-Lyon, L. R., Deming, P., Sakoulas, G., & Mercier, R.-C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr301 · Cited by 70
Cohen, E., Dadashev, A., Drucker, M., Samra, Z., Rubinstein, E., & Garty, M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.155 · Cited by 58
Frymoyer, A. R., Guglielmo, B. J., Wilson, S. D., Scarpace, S. B., Benet, L. Z., & Hersh, A. L. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.871 · Cited by 54
Spapen, H. D., van Doorn, K. J., Diltoer, M., Verbrugghe, W., Jacobs, R., Dobbeleir, N., Honoré, P. M., & Jorens, P. G. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-26 · Cited by 52
Li, J., Udy, A. A., Kirkpatrick, C. M. J., Lipman, J., & Roberts, J. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.08.017 · Cited by 51
Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits
Toyoguchi, T., Takahashi, S., Hosoya, J., Nakagawa, Y., & Watanabe, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1985 · Cited by 50
Moyec, L. L., Racine, S. X., Toumelin, P. L., Adnet, F., Larue, V., Cohen, Y., Leroux, Y., Cupa, M., & Hantz, E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200206000-00013 · Cited by 44
Kralovicová, K., Spanik, S., Halko, J., et al. (1997) · Journal of Chemotherapy · doi:10.1179/joc.1997.9.6.420 · Cited by 39
Chung, J., Oh, J. M., Cho, E. M., et al. (2011) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1103900608 · Cited by 38
Methicillin-resistant Staphylococcus Aureus Infection
Bradley, S. (1992) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30449-x · Cited by 38
Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans
Prabaker, K. K., Tran, T. P. ‐., Pratummas, T., Goetz, M. B., & Graber, C. J. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.946 · Cited by 37
Marinho, D. S., Huf, G., Ferreira, B. L., Castro, H. C., Rodrigues, C. R., de Sousa, V. P., & Cabral, L. M. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-236 · Cited by 34
Fisher, B. T., Zaoutis, T. E., Leckerman, K. H., Localio, R. A., & Aplenc, R. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22601 · Cited by 33
Protective Effect of Inactive Ingredients against Nephrotoxicity of Vancomycin Hydrochloride in Rats
Hodoshima, N., Nakano, Y., Izumi, M., Mitomi, N., Nakamura, Y., Aoki, M., Gyobu, A., Shibasaki, S., & Kurosawa, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.68 · Cited by 31
Lemaire, X., Valette, M., Dubreuil, L. J., Yazdanpanah, Y., Senneville, É., Loïez, C., Migаud, H., & Lemaire, X. (2010) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0176-z · Cited by 11
Cited by
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
The Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Neely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., Schumitzky, A., Yamada, W., Jones, B., & Minejima, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02042-17 · Cited by 359
Innovative approaches to optimizing the delivery of vancomycin in individual patients
Pai, M. P., Neely, M., Rodvold, K. A., & Lodise, T. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.016 · Cited by 292
Self-citation
Metadata
- Authors
- van Hal, S. J., Paterson, D. L., & Lodise, T. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-02
- Volume
- 57
- Issue
- 2
- Pages
- 734-744
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2011312924
- Cited by
- 639
- References
- 57
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.